MADRIGAL PHARMACEUTICALS, INC.MDGLEarnings & Financial Report
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.
MDGL Q4 FY2025 Key Financial Metrics
Revenue
$321.1M
Gross Profit
N/A
Operating Profit
$-59.6M
Net Profit
$-58.6M
Gross Margin
N/A
Operating Margin
-18.6%
Net Margin
-18.2%
YoY Growth
210.8%
EPS
$-2.55
MADRIGAL PHARMACEUTICALS, INC. Q4 FY2025 Financial Summary
MADRIGAL PHARMACEUTICALS, INC. reported revenue of $321.1M (up 210.8% YoY) for Q4 FY2025, with a net profit of $-58.6M (up 1.4% YoY) (-18.2% margin).
Key Financial Metrics
| Total Revenue | $321.1M |
|---|---|
| Net Profit | $-58.6M |
| Gross Margin | N/A |
| Operating Margin | -18.6% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
MADRIGAL PHARMACEUTICALS, INC. Q4 FY2025 revenue of $321.1M breaks down across 3 segments, led by Rebates Customer Fees Credits Co Pay Assistance And Other at $208.5M (64.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Rebates Customer Fees Credits Co Pay Assistance And Other | $208.5M | 64.9% |
| Other | $76.0M | 23.7% |
| Chargebacks Discounts For Prompt Pay And Other Allowances | $36.6M | 11.4% |
MADRIGAL PHARMACEUTICALS, INC. Annual Revenue by Year
MADRIGAL PHARMACEUTICALS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $958.4M).
MADRIGAL PHARMACEUTICALS, INC. Quarterly Revenue & Net Profit History
MADRIGAL PHARMACEUTICALS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $321.1M | +210.8% | $-58.6M | -18.2% |
| Q3 FY2025 | $287.3M | +362.0% | $-114.2M | -39.8% |
| Q2 FY2025 | $212.8M | +1353.8% | $-42.3M | -19.9% |
| Q1 FY2025 | $137.3M | — | $-73.2M | -53.4% |
| Q4 FY2024 | $103.3M | — | $-59.4M | -57.5% |
| Q3 FY2024 | $62.2M | — | $-107.0M | -172.0% |
| Q1 FY2024 | $0 | — | $-147.5M | N/A |
| Q4 FY2023 | $0 | — | $-112.2M | N/A |
Income Statement
| Q4 2023 | Q1 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $62.2M | $103.3M | $137.3M | $212.8M | $287.3M | $321.1M |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | 1353.8% | 362.0% | 210.8% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $640.5M | $1.08B | $1.07B | $1.04B | $996.6M | $1.02B | $1.36B | $1.26B |
| Liabilities | $235.2M | $231.5M | $296.1M | $287.9M | $286.0M | $319.4M | $736.7M | $656.9M |
| Equity | $405.3M | $850.8M | $777.2M | $754.4M | $710.6M | $696.0M | $625.7M | $602.7M |
Cash Flow
| Q4 2023 | Q1 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-79.9M | $-149.2M | $-67.0M | $-104.5M | $-88.9M | $-47.1M | $79.8M | $-133.5M |